Hammers Dustin B, Atkinson Taylor J, Dalley Bonnie C A, Suhrie Kayla R, Beardmore Britney E, Burrell Lance D, Horn Kevin P, Rasmussen Kelli M, Foster Norman L, Duff Kevin, Hoffman John M
a Department of Neurology, Center for Alzheimer's Care, Imaging, and Research , University of Utah , Salt Lake City , UT , USA.
b Center for Quantitative Cancer Imaging, Huntsman Cancer Institute , University of Utah , Salt Lake City , UT , USA.
Clin Neuropsychol. 2017 Apr;31(3):531-543. doi: 10.1080/13854046.2016.1278039. Epub 2017 Jan 12.
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) has been used extensively for clinical care and in research for patients with mild cognitive impairment and Alzheimer's disease (AD); however, relatively few studies have evaluated the relationship between RBANS performance and AD imaging biomarkers. The purpose of the current study was to evaluate the association between a relatively new amyloid positron emission tomography imaging biomarker and performance on the RBANS.
Twenty-seven nondemented community-dwelling adults over the age of 65 underwent F-Flutemetamol amyloid- positron emission tomography imaging, along with cognitive testing using the RBANS and select behavioral measures. Partial correlation coefficients were used to identify relationships between the imaging and behavioral markers.
After controlling for age and education, amyloid deposition and RBANS Indexes of Immediate Memory, Delayed Memory, and Total Scale score were significantly correlated (p's < .001, r's = -.73 to -.77, d's = 2.13-2.39), with greater amyloid burden being associated with lower RBANS scores. The Delayed Memory Index was particularly highly associated with F-Flutemetamol binding (r = .59, p < .001, d = 2.39). Neither F-Flutemetamol binding nor RBANS performance was significantly correlated with levels of depression, subjective cognitive difficulties, or premorbid intellect.
Because of the limited use of amyloid imaging in clinical settings due to high cost and lack of reimbursement, these findings suggest that in particular RBANS Delayed Memory Index may be a cost-efficient tool to identify early signs of AD pathology, and its use may enlighten clinical decision-making regarding potential progression to dementia due to AD.
可重复性神经心理状态评估量表（RBANS）已广泛应用于轻度认知障碍和阿尔茨海默病（AD）患者的临床护理及研究；然而，相对较少的研究评估了RBANS表现与AD影像学生物标志物之间的关系。本研究的目的是评估一种相对较新的淀粉样蛋白正电子发射断层扫描成像生物标志物与RBANS表现之间的关联。
27名年龄在65岁以上、居住在社区且未患痴呆症的成年人接受了¹⁸F-氟代甲磺酸淀粉样蛋白正电子发射断层扫描成像，同时使用RBANS进行认知测试并选择行为测量指标。偏相关系数用于确定成像和行为标志物之间的关系。
在控制年龄和教育程度后，淀粉样蛋白沉积与RBANS即时记忆、延迟记忆和总量表得分显著相关（p值<0.001，r值=-0.73至-0.77，d值=2.13 - 2.39），淀粉样蛋白负担越重，RBANS得分越低。延迟记忆指数与¹⁸F-氟代甲磺酸结合尤其高度相关（r = 0.59，p < 0.001，d = 2.39）。¹⁸F-氟代甲磺酸结合和RBANS表现均与抑郁水平、主观认知困难或病前智力无显著相关性。
由于淀粉样蛋白成像在临床环境中因成本高和缺乏报销而使用有限，这些发现表明，特别是RBANS延迟记忆指数可能是一种经济高效的工具，用于识别AD病理学的早期迹象，其使用可能为因AD导致痴呆症潜在进展的临床决策提供启示。
